GSK Stock Overview
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.
GSK plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£14.15|
|52 Week High||UK£34.08|
|52 Week Low||UK£12.81|
|1 Month Change||-2.12%|
|3 Month Change||4.69%|
|1 Year Change||-26.19%|
|3 Year Change||-33.66%|
|5 Year Change||-11.23%|
|Change since IPO||-39.67%|
Recent News & Updates
|GSK||GB Pharmaceuticals||GB Market|
Return vs Industry: GSK underperformed the UK Pharmaceuticals industry which returned 8.6% over the past year.
Return vs Market: GSK underperformed the UK Market which returned -6% over the past year.
|GSK Average Weekly Movement||3.4%|
|Pharmaceuticals Industry Average Movement||5.8%|
|Market Average Movement||5.8%|
|10% most volatile stocks in GB Market||11.1%|
|10% least volatile stocks in GB Market||2.8%|
Stable Share Price: GSK is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: GSK's weekly volatility (3%) has been stable over the past year.
About the Company
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology.
GSK plc Fundamentals Summary
|GSK fundamental statistics|
Is GSK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GSK income statement (TTM)|
|Cost of Revenue||UK£13.40b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 01, 2023
|Earnings per share (EPS)||1.10|
|Net Profit Margin||11.59%|
How did GSK perform over the long term?See historical performance and comparison